Literature DB >> 9852356

Nonimmune hydrops fetalis: fetal and neonatal outcome during 1983-1992.

L S Wafelman1, B H Pollock, J Kreutzer, D S Richards, A A Hutchison.   

Abstract

Prognostic factors for survival of 62 fetuses and neonates with nonimmune hydrops fetalis (NIHF) were studied retrospectively. Twenty-eight infants survived >/=28 days which is 45% for all fetuses and newborns diagnosed with NIHF and 61% for liveborns with unresolved NIHF. Univariate analysis identified that mortality was associated with the presence of >/=2 serous cavity effusions and a need for chest compressions at birth. Multivariate logistic regression analysis confirmed that the presence of >/=2 serous cavity effusions was significantly associated with mortality from NIHF <28 days after birth [OR = 48.2 (CI 3.6, 662.9) (p < 0.004)]. We conclude that, compared to published cases from the 1970s and early 1980s, survival of liveborns with NIHF seems improved. The decrease in stillbirths is more notable. The severity of hydrops at birth is the key determinant for survival.

Entities:  

Mesh:

Year:  1999        PMID: 9852356     DOI: 10.1159/000014080

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  3 in total

1.  The many faces of hydrops.

Authors:  S Christopher Derderian; Cerine Jeanty; Shannon R Fleck; Lily S Cheng; Shabnam Peyvandi; Anita J Moon-Grady; Jody Farrell; Shinjiro Hirose; Juan Gonzalez; Roberta L Keller; Tippi C MacKenzie
Journal:  J Pediatr Surg       Date:  2014-10-29       Impact factor: 2.545

2.  Our Experience of Immune Fetal Hydrops: its Clinical Characteristics and Perinatal Outcome.

Authors:  Arora Devendra; Kumar Reema; Singh Sanjay; Dey Madhusudan
Journal:  J Obstet Gynaecol India       Date:  2021-02-05

3.  Non-Immune Hydrops Fetalis: Do Placentomegaly and Polyhydramnios Matter?

Authors:  Victoria K Berger; Teresa N Sparks; Angie C Jelin; Chris Derderian; Cerine Jeanty; Kristen Gosnell; Tippi Mackenzie; Juan M Gonzalez
Journal:  J Ultrasound Med       Date:  2017-10-27       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.